Indiana University School of Medicine researchers have developed a new breast cancer diagnostic marker that could enable physicians to more easily determine which patients have a less aggressive form of the disease that may not require chemotherapy treatment. The marker has been licensed by Clarient Inc., a California-based cancer diagnostics company that plans to develop a commercial test based on the research by Harikrishna Nakshatri, B.V.Sc., Ph.D., Marian J.
More...
Linear Mode
